Evidence map›Paper›PMID 25036526›Full record

ArticlePloS one2014

Absence of BRCA/FMR1 correlations in women with ovarian cancers.

Norbert Gleicher, Jessica N McAlpine, C Blake Gilks, Vitaly A Kushnir, Ho-Joon Lee, Yan-Guang Wu, Emanuela Lazzaroni-Tealdi, David H Barad

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Norbert GleicherCenter for Human Reproduction, New York, New York, United States of America; Foundation for Reproductive Medicine, New York, New York, United States of America.
Jessica N McAlpineDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of British Columbia, Vancouver, British Columbia, Canada; OvCaRe Gynecologic Tissue Bank, BC Cancer Agency, Vancouver, British Columbia, Canada.
C Blake GilksOvCaRe Gynecologic Tissue Bank, BC Cancer Agency, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Vitaly A KushnirCenter for Human Reproduction, New York, New York, United States of America.
Ho-Joon LeeCenter for Human Reproduction, New York, New York, United States of America.
Yan-Guang WuCenter for Human Reproduction, New York, New York, United States of America.
Emanuela Lazzaroni-TealdiCenter for Human Reproduction, New York, New York, United States of America.
David H BaradCenter for Human Reproduction, New York, New York, United States of America; Foundation for Reproductive Medicine, New York, New York, United States of America.
Center for Human Reproduction · USBC Cancer Agency · CAFoundation for Reproductive Medicine · USUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously reported findings in Austrian BRCA1/2 mutation carriers suggested a possible dependency of embryos with BRCA1/2 mutations on so-called low alleles of the fragile X mental retardation 1 (FMR1) gene, characterized by less than 26 CGG repeats (CGG(n<26)). The hypothesis arose from a study reporting highly statistically significant enrichment of low FMR1 alleles, significantly exceeding low allele prevalence in a general population, suggesting embryo lethality of BRCA1/2 mutations, "rescued" by presence of low FMR1 alleles. Such a dependency would also offer an explanation for the so-called "BRCA-paradox," characterized by BRCA1/2 deficient embryonic tissues being anti-proliferative (thereby potentially causing embryo-lethality) but proliferative in malignant tumors, including breast and ovarian cancers. Follow up investigations by other investigators, however, at most demonstrated trends towards enrichment but, mostly, no enrichment at all, raising questions about the original observation and hypothesis. We in this study, therefore, investigated CGGn of the FMR1 gene of 86 anonymized DNA samples from women with various forms of ovarian cancer, and were unable to demonstrate differences in prevalence of low FMR1 alleles either between positive and negative ovarian cancer patients for BRCA1/2 or between ovarian cancer patients and reported rates in non-cancer populations. This raises further questions about a suggested dependency between BRCA1/2 and FMR1, but also raises the possibility that investigated Austrian BRCA1/2 carrier populations differ from those in other countries. Either only selected BRCA1/2 mutations, therefore, interact with low FMR1 alleles or the Austrian data reflect only coincidental observations.

Indexed as

AllelesBRCA1 ProteinBRCA2 ProteinCase-Control StudiesFemaleFragile X Messenger Ribonucleoprotein 1Genetic Predisposition to DiseaseGenotypeHumansMutationOvarian NeoplasmsBRCA1 ProteinBRCA2 ProteinFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1

Identifiers

PMID25036526
PMCPMC4103842
OpenAlexW2087871573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.